Insider Trading Activity For Nektar Therapeutics (NASDAQ:NKTR)
Roy A Whitfield , Director of Nektar Therapeutics (NASDAQ:NKTR) reportedly Bought 35,000 shares of the company’s stock at an average price of 17.95 for a total transaction amount of $628,250.00 SEC Form
Insider Trading History For Nektar Therapeutics (NASDAQ:NKTR)
Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR)
These are 9 Buy Ratings .
The current consensus rating for Nektar Therapeutics (NASDAQ:NKTR) is Buy (Score: 3.00) with a consensus target price of $27.13 , a potential (40.69% upside)
Analyst Ratings History For Nektar Therapeutics (NASDAQ:NKTR)
- On 1/27/2016 Janney Montgomery Scott Initiated Coverage of rating Buy with a price target of $21.00
- On 9/30/2016 Brean Capital Reiterated Rating Buy with a price target of $23.00
- On 3/21/2017 J P Morgan Chase & Co Set Price Target of rating Buy with a price target of $24.00
- On 3/21/2017 BTIG Research Boost Price Target of rating Positive with a price target of $22.00 to $27.00
- On 4/11/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $29.00
- On 5/10/2017 Aegis Reiterated Rating Buy with a price target of $27.00
- On 7/18/2017 William Blair Reiterated Rating Outperform
Recent Trading Activity for Nektar Therapeutics (NASDAQ:NKTR)
Shares of Nektar Therapeutics closed the previous trading session at 19.28 up +1.02 5.59% with 1,240,270 shares trading hands.